Status:
RECRUITING
Effects of Pasireotide Lar Therapy on Bone Metabolism
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Acromegaly Due to Pituitary Adenoma
Acromegaly
Eligibility:
All Genders
18+ years
Brief Summary
Acromegaly, a chronic condition characterized by growth hormone (GH) and, in turn, insulin-like growth factor-1 (IGF-I) excess, is burdened by a series of systemic and metabolic comorbidities that str...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA FOR THE PROSPECTIVE COHORT
- adult patients (\>18 years)
- acromegaly not-controlled after 6 months of treatment with fg-SRLs and switched since at least one week, to Pasireotide LAR, according to clinical practice and actual experts consensus,
- signing of informed consent
- INCLUSION CRITERIA FOR THE RETROSPECTIVE COHORT
- adult patients (\>18 years)
- acromegaly not-controlled after 6 months of treatment with fg-SRLs and switched to Pegvisomant, according to clinical practice and actual experts' consensus,
- signing of informed consent or substitute declaration on the consent form where applicable.
- Exclusion Criteria:
- patients under the age of 18 years.
Exclusion
Key Trial Info
Start Date :
September 8 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07179926
Start Date
September 8 2025
End Date
June 1 2028
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS UOC Endocrinologia e Diabetologia
Rome, RM, Italy, 00168